Tag Archives: osteoporosis

July, 2018

  • 13 July

    Amgen and UCB Resubmit BLA for Evenity to the FDA for the Treatment of Osteoporosis

    THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone …

May, 2018

November, 2017

July, 2017

May, 2017

April, 2017

September, 2016

August, 2016

  • 29 August

    Amgen Announces Positive Top-Line Results from Late-Stage Prolia Study

    THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all …